QPPV.COM KNOWLEDGE ASSESSMENT

Knowledge Assessment: Recombinant Therapeutic Proteins—Classification and Pharmacovigilance

Test your understanding of the concepts covered by Recombinant Therapeutic Proteins: Classification and Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 A laboratory change occurs during treatment with a recombinant growth factor. What should be considered before classifying it as an adverse reaction?

Whether it may be an expected pharmacodynamic consequence of the intended mechanism Whether all laboratory changes with biologicals are automatically adverse reactions Whether the product is a biosimilar, without considering its mechanism Whether the event was reported within one day, regardless of biology

Question 2 of 10 Why can the administration date alone be insufficient when assessing the timing of a safety event with a recombinant protein?

Administration dates are never needed in case assessment Prolonged half-life or sustained biological activity may produce effects after concentrations or administration events change Protein exposure always ends immediately after administration The timing of an event is determined only by its seriousness

Question 3 of 10 Which statement best describes the role of general EU GVP and biological-product considerations?

Biological-product guidance replaces the general GVP modules General GVP applies, while biological-product guidance supplies additional scientific context for complexity, traceability and immunogenicity General GVP applies only to small molecules Biological medicines are governed only by product-specific guidelines

Question 4 of 10 Which sequence best represents the conceptual relationship between production and pharmacovigilance assessment?

Clinical event → manufacturing process → amino-acid sequence → regulatory action Recombinant expression → molecular characteristics → biological activity → exposure and target engagement → clinical outcome Batch number → adverse-event count → expression system → clinical effect Indication → formulation → regulatory status → protein sequence

Question 5 of 10 A patient develops bleeding despite treatment with a recombinant coagulation factor. Which set of information is most relevant to the assessment?

Only the total number of bleeding reports for the product Product and dose, treatment timing, factor activity, inhibitor testing, adherence and bleeding context Only the patient’s age and sex Only whether the product was manufactured recombinantly

Question 6 of 10 Why does a negative antibody test not necessarily exclude an immune-mediated explanation for a clinical event?

Antibody testing is never useful for therapeutic proteins The test may be affected by timing, sensitivity, drug interference or immune mechanisms not detected by that assay Negative tests establish that the product was not administered Immune responses occur only after treatment has stopped

Question 7 of 10 A patient receiving a replacement protein experiences loss of therapeutic effect. Which initial approach is most scientifically appropriate?

Classify the event automatically as neutralising immunogenicity Assess dose, administration, adherence, disease status, pharmacokinetics, antibodies and other possible causes Exclude immunogenicity because the patient previously responded Treat the event as a manufacturing defect until batch testing is complete

Question 8 of 10 Which organisational response is most appropriate when a suspected manufacturing-related safety concern emerges?

Assign the matter exclusively to pharmacovigilance and close the quality assessment Assign the matter exclusively to quality and exclude clinical safety review Conduct coordinated quality and pharmacovigilance assessments with defined information-sharing and escalation Wait for definitive causality before involving any other function

Question 9 of 10 Which denominator may be most appropriate for a quantitative safety analysis of a recombinant protein?

The number of manufacturing sites only A suitable exposure measure such as treated patients, doses, treatment cycles or person-time The number of countries in which the product is authorised The number of product variants regardless of exposure

Question 10 of 10 Which statement most accurately distinguishes a plausible mechanism from a causal conclusion in an individual case?

A biologically plausible mechanism proves causality A mechanism is irrelevant unless supported by a positive antibody test A plausible mechanism guides evidence collection but must be assessed against chronology, clinical data and alternative explanations Causality can be established solely from the product class

QPPV.com

Knowledge Assessment: Recombinant Therapeutic Proteins—Classification and Pharmacovigilance

Cookie Settings